Aligos Therapeutics (NASDAQ:ALGS – Get Rating) is set to release its earnings data after the market closes on Thursday, March 9th. Analysts expect Aligos Therapeutics to post earnings of ($0.49) per share for the quarter.
Aligos Therapeutics Stock Performance
Shares of ALGS opened at $1.51 on Thursday. Aligos Therapeutics has a 52-week low of $0.84 and a 52-week high of $2.99. The stock has a 50 day simple moving average of $1.55 and a 200 day simple moving average of $1.26. The firm has a market capitalization of $64.66 million, a PE ratio of -0.57 and a beta of 2.44.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALGS. PDT Partners LLC acquired a new position in Aligos Therapeutics in the 1st quarter valued at $57,000. AQR Capital Management LLC acquired a new position in Aligos Therapeutics in the 2nd quarter valued at $58,000. Prelude Capital Management LLC acquired a new position in Aligos Therapeutics in the 1st quarter valued at $58,000. Mirabella Financial Services LLP acquired a new position in Aligos Therapeutics in the 1st quarter valued at $88,000. Finally, XTX Topco Ltd acquired a new position in Aligos Therapeutics in the 1st quarter valued at $94,000. 64.53% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
About Aligos Therapeutics
Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.
- Get a free copy of the StockNews.com research report on Aligos Therapeutics (ALGS)
- Jack in the Box Pops On Tasty Results, Robust Outlook
- How Low Can Lowe’s Companies Go?
- Ambarella: An AI Play In The Making
- Wendy’s Price Firms After Sizzling Quarter And Juicy Outlook
- Terran Orbital’s New $2.4 Billion Contract is a Game Changer
Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.